European Medicines Agency Recommends Astellas' Arpraziquantel For Treatment Of Schistosomiasis In Preschool-Aged Children
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency has recommended Astellas Pharma Inc.'s drug, Arpraziquantel, for the treatment of schistosomiasis in preschool-aged children. This recommendation could lead to increased use of the drug in this age group across Europe.
December 18, 2023 | 6:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astellas Pharma Inc.'s Arpraziquantel has been recommended by the EMA for treating schistosomiasis in preschool-aged children, which may lead to an expanded market for the drug in Europe.
The EMA's recommendation is a significant regulatory milestone that can lead to increased adoption and sales of Arpraziquantel in Europe, particularly for the pediatric segment. This positive development is likely to be viewed favorably by investors, potentially leading to a short-term uptick in Astellas Pharma Inc.'s stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90